OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRPα antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Advanced Solid Tumors

Ads

You May Also Like